Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLife SolutionsBLFS -0.70%73 EV-to-EBIT is 551.85 as of Aug. 14, 2026. GuruFocus rates BLFS with a GF Score™ of 73/100 and a GF Value™ of $29.99 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 473 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 98.94% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
BioLife Solutions's Enterprise Value for the quarter that ended in Jun. 2026 was $1,313.9 Mil.
BioLife Solutions's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLife Solutions EV-to-EBIT Related Terms
BioLife Solutions EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, BioLife Solutions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's EV-to-EBIT falls into.
BioLife Solutions's current Enterprise Value is $1,645.1 Mil.
BioLife Solutions's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLife Solutions (BLFS) has a EV-to-EBIT of 551.85 as of Aug. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BioLife Solutions and its competitors. According to the industry distribution chart, BioLife Solutions ranks #468 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 98.9%.
Is BioLife Solutions' EV-to-EBIT too high?
BioLife Solutions' current EV-to-EBIT is 551.85. The Medical Devices & Instruments industry median EV-to-EBIT is 19.17. BioLife Solutions' value of 551.85 is 2778.7% above this industry median. Based on the distribution chart, BioLife Solutions ranks #468 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BioLife Solutions has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' EV-to-EBIT compare to AZTA and KMTS?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #468 out of 473 companies for EV-to-EBIT. This places BioLife Solutions in the lower half of its industry. The industry median EV-to-EBIT is 19.17. BioLife Solutions' value of 551.85 is 2778.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.17, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current EV-to-EBIT of 551.85 is 2778.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current EV-to-EBIT is 551.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.99, compared to a current price of $35.00 — trading 16.7% above its estimated fair value. The current EV-to-EBIT is 551.85 and 2778.7% above the Medical Devices & Instruments industry median of 19.17. BioLife Solutions' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current EV-to-EBIT is 551.85 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of $35.00 is trading 16.7% above its estimated GF Value™ of $29.99.
GuruFocus considers BioLife Solutions to be Modestly Overvalued.
Key valuation signals for BLFS:
EV-to-EBIT: 551.85
GF Value™: $29.99 vs. price of $35.00 (16.7% above fair value)
Industry Position: 2778.7% above the Medical Devices & Instruments median (#468 of 473)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
73GF Score
Get the complete analysis for BLFS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
